Tigecycline

Resistance to antibiotics in northern Nigeria: what bacteria are prevalent, and which drugs work against them

Retrieved on: 
Sunday, September 17, 2023

Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.

Key Points: 
  • Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.
  • The continent has the highest global burden of antimicrobial-resistant infections, with 114.8 deaths per 100,000 people.
  • Physicians need laboratory data to choose the right antibiotic, at the right dose, for the right period of time.
  • This can lead to choosing ineffective antibiotics, which can lead to increases in resistant bacteria.
  • In other words, to develop a list of what bacteria are prevalent in the region and which drugs work against them.
  • To accomplish this, we recently conducted a study of multidrug-resistant bacteria obtained from patients in six hospitals in northern Nigeria.

Drug-resistant bacteria in Nigeria

    • We chose to analyse bacteria that are resistant to more than one drug because they are the biggest challenge when treating infections.
    • We found that about 85% of the bacteria isolated from infections were resistant to the most commonly used antibiotics.
    • The good news was that two antibiotics, tigecycline and fosfomycin, remained very active even against highly resistant strains of bacteria.

Genetic mechanisms

    • This was done to understand what made these organisms so resistant to antibiotics at the molecular level.
    • The data revealed an astonishingly high number of genetic mechanisms making the microorganisms resistant.
    • In some cases, the genetic information encoding resistance was capable of being shared among other microorganisms.

The need for antimicrobial stewardship

    • Some of the resistance genes were capable of moving from one microorganism to another (mobile resistance genes).
    • Antimicrobial stewardship based on laboratory data is effective especially if done locally, regionally and nationally.

Antimicrobial resistance is everyone’s concern

    • Read more:
      Antimicrobial resistance calls for brainpower of a space agency and campaigning zeal of an NGO

      Fourth, there are things that everyone can do to help bring antibiotic resistance under control.

    • For example, the US Centers for Disease Control and Prevention list five things that everyone should know about drug resistance and 10 activities to protect yourself and your family against resistance.
    • He is affiliated with the International Society for Antimicrobial Chemotherapy.

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220808005491/en/
    Scott T. Rottinghaus, M.D., Senior Vice President and Chief Medical Officer, Enanta Pharmaceuticals (Photo: Business Wire)
    We are delighted to welcome Scott Rottinghaus to our senior management team.
  • Earlier in his Pfizer career, he worked as a clinician on early stage clinical trials for influenza vaccine development.
  • Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release.

Investigation Report on China's Tigecycline Markets, 2016-2020 & 2021-2025: A Broad-spectrum Glycyl Cyclic Peptide Antibiotic Administered Intravenously - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022

The "Investigation Report on China's Tigecycline Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Tigecycline Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously.
  • Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over.
  • By 2020, tigecycline has been included in China's Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.

Global Hospital Infection Therapeutics Market Report 2021: Market Reached a Value of Approx $11 Billion in 2020 - Trends, Share, Size, Growth, Opportunities and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 24, 2022

The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020.
  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global hospital infection therapeutics market and who are the key players?

New Research Found Cannabidiol is Active Against Gram-Positive Bacteria

Retrieved on: 
Tuesday, March 3, 2020

We learned recently, the American Society for Microbiology found CBD is an active ingredient against Gram-positive Bacteria.

Key Points: 
  • We learned recently, the American Society for Microbiology found CBD is an active ingredient against Gram-positive Bacteria.
  • The article goes on to say it is active against those including serious infections such as Staphylococcus aureus and Streptococcus pneumonia.
  • Mr. Paul Rosenberg, CEO of MCIG, goes on to state, It is the reason we chose BareRoots Rx as our joint venture partner to form BRRX Clinical Inc.
  • We here at BRRX Clinical Inc. are offering special pricing to serve our public during these challenging times.